
LogicBio Therapeutics LOGC
Quarterly report 2022-Q3
added 11-14-2022
LogicBio Therapeutics Long Term Debt Current 2011-2026 | LOGC
Annual Long Term Debt Current LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.23 M | 1.09 M | 504 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.23 M | 504 K | 942 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Veracyte
VCYT
|
4.05 M | $ 30.92 | -5.73 % | $ 2.43 B | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
8.92 M | $ 12.67 | -9.24 % | $ 1.92 B | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 321.51 | -2.03 % | $ 42.1 B | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
363 K | $ 1.91 | -7.28 % | $ 109 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.46 | -0.36 % | $ 910 M | ||
|
Amarin Corporation plc
AMRN
|
2.15 M | $ 14.23 | -2.97 % | $ 5.91 B | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 45.99 | -3.28 % | $ 4.14 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
547 K | $ 4.33 | -2.81 % | $ 830 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M |